Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617

Prostate cancer (PC) is one of the most common malignancies affecting men, with poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapy (RLT) targeting the overexpressed PSMA on PC cells, with, e.g., <sup>177</sup>Lu-PSMA-617, has...

Full description

Bibliographic Details
Published in:Pharmaceutics
Main Authors: Amanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, Joanna Strand, Sven-Erik Strand, Bo Åkerström, Anders Örbom
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Subjects:
radioligand therapy
<sup>177</sup>Lu-PSMA-617
prostate cancer
mouse model
hematotoxicity
Online Access:https://www.mdpi.com/1999-4923/14/4/731

Internet

https://www.mdpi.com/1999-4923/14/4/731

Similar Items